GLUE Stock — Monte Rosa Therapeutics Inc.: Cash, EV, Pipeline

Share price

$12.13

Market cap

$1,034.9M

Cash

$621.1M

Enterprise value

$413.8M

Balance sheet

Cash	$621.1M
Debt	$0.0M
Net cash	$621.1M
Enterprise value	$413.8M
Basic shares	85.2M shares
Fully diluted shares	106.1M shares
Fully diluted market cap	$1,286.9M
Cash per share	$7.29

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GLUE daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Now - Sep 23, 2026	MRT-8102	Phase 1	Healthy Volunteers; Elevated CRP	—
Nov 12 - Dec 24	Oral MRT-2359	Phase 2	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

MRT-2359

Stage not disclosed · Active Modality: molecular glue degrader

Target GSPT1

Indications

NSCLC (Phase 2)
SCLC (Phase 2)
High Grade Neuroendocrine Cancer (Phase 2)

Status note GSPT1-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

MRT-8102

Stage not disclosed · Active Modality: molecular glue degrader

Target NEK7

Indications

not disclosed (Stage not disclosed)

Status note NEK7-directed MGD; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

MRT-6160

Stage not disclosed · Active Modality: molecular glue degrader

Target VAV1

Partnerships Novartis: license agreement (2024) for MRT-6160 and other discovery programs

Indications

not disclosed (Stage not disclosed)

Status note VAV1-directed MGD out-licensed to Novartis; clinical trials referenced in primary filing. Stage/indication detail appears only in the 10-K fallback section and is not populated.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Oral MRT-2359
Lead indication	Castration-Resistant Prostate Cancer (CRPC)
Lead phase	Phase 2
Active trials	3

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT07745361	Phase 2	Recruiting	Sponsor	GLUE	—	Castration-Resistant Prostate Cancer (CRPC); Castration-Resistant Prostate Cancer; Prostate Cancer	—
NCT05546268	Phase 2	Active, not recruiting	Sponsor	GLUE	—	NSCLC; SCLC; High Grade Neuroendocrine Cancer	—
NCT07119125	Phase 1	Active, not recruiting	Sponsor	GLUE	—	Healthy Volunteers; Elevated CRP	—

Sponsor-matched active trials from ClinicalTrials.gov (3 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 3 active trials for Monte Rosa Therapeutics, Inc on ClinicalTrials.gov

Institutional holders

Fund	Shares	Q/Q change	% of portfolio	Filing
Baker Bros. Advisors	4,345,736	no change	0.53%	2026-08-14
Braidwell LP	2,451,562	-755,012	2.19%	2026-08-14
Frazier Life Sciences	1,000,000	no change	0.53%	2026-08-14
ADAR1 Capital Management	216,752	+1,000	0.25%	2026-08-14

Institutional holder positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.

GLUE — Monte Rosa Therapeutics Inc.

Balance sheet

Price history

Upcoming catalysts

Pipeline assets

Pipeline

Active clinical trials

Institutional holders